SCHEMBL25325827

SCHEMBL25325827

CC1CC=C(c2ccc3cn(C)nc3c2)NC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 2/20 0.44
▸ CREBBP Q92793 2/20 0.44
▸ MAPT P10636 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ NSD2 O96028 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ SCD5 Q86SK9 1/20 0.36
▸ KIT P10721 3/20 0.34
▸ PDGFRA P16234 3/20 0.34
▸ KDR P35968 3/20 0.34
▸ JAK3 P52333 3/20 0.34
▸ JAK2 O60674 2/20 0.33
▸ PRMT5 O14744 2/20 0.33
▸ MAT2A P31153 1/20 0.33
▸ BRAF P15056 1/20 0.32
▸ FLT3 P36888 1/20 0.32
▸ SYK P43405 1/20 0.32
▸ GSK3B P49841 1/20 0.32
▸ MET P08581 1/20 0.32
▸ CTSC P53634 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30886358 0.90 MAT2A (0.36) BRD4CREBBPKDM4EMAT2A
SCHEMBL25319673 0.80 BRD4 (0.32) BRD4CREBBP
SCHEMBL30886277 0.76 ALDH1A1 (0.43) ALDH1A1PDGFRAGSK3B
SCHEMBL30886362 0.74 ERCC1 (0.43) CREBBPSCD5FLT3SYKGSK3B
SCHEMBL29982007 0.74 MAP4K1 (0.39) PRMT5
SCHEMBL30886382 0.73 TDO2 (0.36) KDR
SCHEMBL24364283 0.73 PRKCZ (0.42) BRD4CREBBPKDRGSK3B
SCHEMBL30886424 0.73 KDM4E (0.37) MAPTKDM4EALDH1A1
SCHEMBL30886292 0.72 CREBBP (0.44) BRD4CREBBPFLT3SYK
SCHEMBL30886326 0.72 KMT2A (0.42) MAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163048-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-22 — — US disclosed
EP-4469455-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 — — EP disclosed
CN-118047793-A Pyridine derivative and application thereof 成都百裕制药股份有限公司 2024-05-17 — — CN disclosed
WO-2023146990-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 — — WO disclosed
WO-2023146990-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163048-A1 COMPOUNDS AND METHODS OF USE RB1, CYP1B1, REN BRD4 1725/4885CREBBP 2491/4885MAPT 2959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback